MeSH tree: C15.604.515
Researchers at The University of Texas MD Anderson Cancer Center have characterized the complex microenvironment in angioimmunoblastic T cell lymphoma (AITL), a type of nodal T cell lymphoma, and identified overexpression ...
Dec 9, 2025
0
0
Patients who receive T-cell redirecting therapies are typically hospitalized for several days after treatment to watch for side effects. Now new research by Fox Chase Cancer Center physicians shows that these patients can ...
Dec 9, 2025
0
0
Aggressive T-cell lymphoma is a rare and devastating form of blood cancer with a very low five-year survival rate. Patients often relapse after receiving initial therapy, making it especially challenging for clinicians to ...
Dec 8, 2025
0
0
A new treatment using genome-edited immune cells, developed by scientists at UCL (University College London) and Great Ormond Street Hospital (GOSH), has shown promising results in helping children and adults fight a rare ...
Dec 8, 2025
0
12
Measuring the lymphocytes—white blood cells that fight infection—in a patient's blood can be used to predict outcomes in non-Hodgkin lymphoma patients who receive CAR T-cell therapy, according to research from physicians ...
Dec 8, 2025
0
0
Most patients with a rare and aggressive form of large B-cell lymphoma can safely receive a less toxic treatment than the intensive chemotherapy often used, according to new research from Sylvester Comprehensive Cancer Center, ...
Dec 8, 2025
0
0
New three-year follow-up results from the TRANSCEND FL trial show that patients with relapsed or refractory follicular lymphoma can achieve durable, multi-year remission with chimeric antigen receptor (CAR) T cell therapy, ...
Dec 8, 2025
0
0
According to a new trial, patients with chronic lymphocytic leukemia (CLL) show comparable outcomes whether they receive a single-agent treatment indefinitely or a combination treatment for a fixed period of time.
Dec 8, 2025
0
1
In a new trial, patients with follicular lymphoma had a significantly higher response to treatment and a nearly 80% reduction in the risk of death or disease progression if they received epcoritamab in addition to the standard ...
Dec 8, 2025
0
0
Pirtobrutinib, a non-covalent Bruton tyrosine kinase (BTK) inhibitor, met the primary endpoint for non-inferiority in terms of overall response rate in the first head-to-head comparison with ibrutinib, a covalent BTK inhibitor. ...
Dec 8, 2025
0
0
